AaronYoshioMochizukiDO

Pediatric Hematology & Oncology • Cincinnati, OH

Pediatric Neuro-Oncology

Physician

Join to view full profile

Dr. Mochizuki is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mochizuki's full profile

Already have an account?

Office
3333 Burnet Ave
Cincinnati, OH 45229

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Neuro-Oncology, 2019 - 2021
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 2016 - 2019
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Pediatrics, 2013 - 2016
University of HawaiiInternship, Pediatrics, 2013 - 2014
A.T. Still University, School of Osteopathic Medicine in ArizonaClass of 2013

Certifications & Licensure

IN State License 2021 - 2025
KY State License 2021 - 2025
OH State License 2021 - 2025
CA State License 2014 - 2024
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

875 citations
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla, Willy Hugo, Alexander Lee
Nature Medicine. 2019-02-11
398 citations
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Robbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, Shabnum Patel, Harshini Chinnasamy
Nature. 2022-03-01
119 citations
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
Alexander Lee, Lu Sun, Aaron Mochizuki, Jeremy Reynoso, Joey Orpilla
Nature Communications. 2021-11-26

Press Mentions

ASCO Reading Room | Neoadjuvant ImmunoTx for Recurrent GlioblastomaMarch 30th, 2019